A Comprehensive Review of the Most Important Presentations from the 2020 San Antonio Breast Cancer Symposium

February 12, 2021

This program will provide a comprehensive review of the most important presentations from the 2020 San Antonio Breast Cancer Symposium.

Target Audience

Physicians, researchers, advanced practice providers, nurses, and other health care professionals who work with individuals with breast cancer.

Learning Objectives

Upon completion of this program, attendees will be able to:

• Identify the most up to date findings in breast cancer clinical and translational research.
• Incorporate research findings to appropriately manage patients with breast cancer.
• Demonstrate understanding of the scientific findings in breast cancer research by demonstrating competence in the clinical setting.

Additional Information

AttachmentSize
PDF icon SABCR Brochure- handout final.pdf218.13 KB
Course summary
Available credit: 
  • 4.75 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  • 4.75 Attendance
Course opens: 
12/09/2020
Course expires: 
06/30/2021
Event starts: 
02/12/2021 - 8:00am
Event ends: 
02/12/2021 - 3:00pm
Cost:
$1.00

Agenda

 

8:30 am

Welcome- Shannon Puhalla, MD; Dr Dhaval Mehta, MD

 

8:35 am

Breast Surgery Updates – Emilia Diego, MD

 

8:55 am

Pathology Update – Beth Clark, MD

 

9:10 am

Radiology Updates – Austin Vargo, MD

 

9:25 am

Questions and Answers

 

9:35 am

Adjuvant Options in High Risk ER+ Breast Cancer – Priya Rastogi, MD

 

9:55 am

Genomics Testing Updates in ER+ Breast Cancer – Adam Brufsky, MD, PhD

 

10:15 am

Questions and Answers

 

10:30 am

Survivorship Update – Josie van Londen, MD, MSc

 

10:40 am

Basic Science – ESR1 hotspot mutations – Steffi Oesterreich, PhD

 

10:55 am

Questions and Answers

 

11:05 am

Break/ Vendor Breakout Sessions

 

11:20 am

Immunotherapy in Triple Negative Breast Cancer – Leisha Emens, MD, PhD

 

11:40 am

Chemotherapy in ER+ Breast Cancer – Vikram Gorantla, MD

 

12:00 pm

Updates in Her2neu + Breast Cancer – Kit Lu, MD

12:20 pm

Questions and Answers

 

12:30 pm

Basic Science- Brain Mets/Breast Cancer – Adrian Lee, PhD

 

12:40 pm

Novel Agents/NSABP trials – Shannon Huggins-Puhalla, MD

 

1:00 pm

Monday Morning/COVID 19/UPMC community trials – Dhaval Mehta, MD; Terry Evans, MD

 

1:20 pm

Final Comments – Dhaval Mehta, MD, and  Shannon Puhalla, MD

 

1: 30 pm

Adjournment

 

 

Course Handouts:

Presentations will not be printed. A copy of presentation slides can be accessed via UPMC MyCloud. Instructions on how to access program slides will be emailed to the email address that was provided during online registration.

Live Virtual Conference

This conference will be held virtually via Microsoft TEAMS; a link for the conference will be sent to all participants enrolled in the conference.

Faculty Disclosure:

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

Adam Brufsky, MD, PhD – Consultant: Puma, Seattle Genetics, Daiichi, Roche, AstraZeneca, Pfizer, Novartis

Emilia Diego, MD – Other: DSMB Xoft, Inc.

John Austin Vargo, MD – Other: Clinical Pathways, Elsevier

Kit Lu, MD – CE Speakers’ Bureau: AstraZeneca, Daiichi Sankyo, Seattle Genetics

Leisha A. Emens, MD, PhD – Global Clinical Trial Steering Committees/Data Safety Monitoring Boards: Co-Chair Impassion130 Steering Committee (Genentech/Roche), Chair KATE2 Steering Committee (Genentech/Roche), Chair TRIO-025 DSMB (Trio/Syndax), Ambiance Trial Steering Committee Member. Consulting/Advisory Board/Honoraria: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Chugia, CytomX, eTheRNA,  Genentech, Gilead, GPCR Therapeutics, Gritstone, JKTG Foundation, Medimmune, Molecuvax, Marcrogenics, Novartis, Peregrine, Replimune, Roche, Shionogi, Silverback, Syndax, Vaccinex; Grant/Research Support:  Aduro Biotech, AstraZeneca, Bolt, Breast Cancer Research Foundation, Bristol Meyer Squibb, Corvus, Department of Defense, EMD Serono, Genentech, HertiX, Inc., Maxcyte, Merck, National Cancer Institute, NSABP Foundation, Roche, Silverback/AACR, Su2C, Tempest, Translational Breast Cancer Research Consortium, Royalties: Aduro IND Licensing/vaccine

Shannon Puhalla, MD – Grant/Research Support: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covariance-Bayer, AstraZeneca; Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, nanostring

Vikram Gorantla, MD – Consultant: IntegraConnect

Priya Rastogi, MD – Consultant: Advisory Board for Genentech; Other: Travel & Accommodations Lilly, Genentech, AstraZeneca

Steffi Oesterreich, PhD – Grant/Research Support: AstraZeneca, Illumina, H3 Biomedicine, Blueprint Medicine, Zentalis, Advisory Board NSABP; NCI, BCRF, Susan G Komen, MBCN, Breast Cancer Alliance; Other: NASBP, McGill University, Georgetown.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)
The University of Pittsburgh designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Available Credit

  • 4.75 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  • 4.75 Attendance

We gratefully acknowledge support from the following for this activity:

Exhibitors:

AstraZeneca – ADC Franchise, Enhertu

AstraZeneca – DDR

Lilly Oncology

Seagen

Novartis

Eisai

Merck

Puma Biotechnology

Daiichi Sankyo

Genentech – member of the Roche group

Agendia Inc.

Price

Cost:
$1.00
Please login or register to take this course.

Online registration is now closed. For more information, contact Becky McClelland at mcclellandr2@upmc.edu.

Registration categories and fees:
non-UPMC Physicians  ($75)
non-UPMC medical professionals ($50)
UPMC Physicians and medical professionals ($0)

All cancellations must be sent via email, [mcclellandr2@upmc.edu].  Cancellations received before [01/22/2021] will be refunded in full.  After [02/01/2021],  and no refunds will be made after [02/01/2021].